- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02109835
Progression of Coronary Atherosclerosis in Asymptomatic Diabetic Subjects (PROCEED)
Progression of Coronary Atherosclerosis in Asymptomatic Diabetic Subjects: Evaluation of the Role of CT Coronary Angiography and Novel Bio-markers of Endothelial Dysfunction and Vascular Inflammation
Study Overview
Status
Conditions
Detailed Description
Hypothesis: We hypothesise that a combination of CT coronary angiography, ultrasound of the heart and of the arteries of the neck, evaluation of expression of genetic markers and bio-markers in the blood will help identify diabetic patients at highest risk of heart disease progression,that can result in angina, heart attacks, heart failure and cardiovascular deaths.
Previous studies using coronary calcium scanning in diabetic patients showed that those with the greatest progression in calcified plaque in the coronary arteries were at the highest risk for heart attacks. However, coronary calcium scans only identify the calcified plaque and are not able to pick up non-calcified, cholesterol rich plaques. Cholesterol rich non-calcified plaques are more often associated witn acute heart attacks. CT coronary angiography can identify both calcified and non-calcified plaques and can therefore add significantly to our predictive ability. Certain chemical substances (biomarkers) measured in blood indicate the severity of plaque burden and inflammation in the coronary arteries. A combination of CT coronary angiography, expression of genetic markers, measure of function of the cells lining the blood vessels and biomarkers can help to identify diabetic patients at highest risk of heart attacks, allowing us to start appropriate risk reduction treatments in those patients. In previous studies with coronary artery calcium, patients suffering from heart attacks were those who also had a higher progression of coronary artery calcium (CAC) score. In diabetics, in particular, patients with poor control of their blood glucose also had greater progression of the CAC score. In order to test the validity of our hypothesis, we have decided to base our study on a population of established diabetics with difficult to control blood pressure, high cholesterol and chronic complications of the small blood vessels, i.e. involvement of the retina (back of the eye) and peripheral nerves as well as protein in the urine. Patients with chronic complications of diabetes are known to have higher incidence of heart disease as well.
Methodology and Timetable: Patients will be recruited from Diabetes clinics of NHS hospitals in North West London.
If eligible for the trial, an informed consent will be obtained from the patients and their general practitioner will be subsequently informed about their participation in the trial. Once recruited into the trial, a CT coronary angiogram (CTCA, CT of the arteries of the heart), ultrasound scan of the heart and carotid arteries of the neck as well as a measure of endothelial function will be performed at the Wellington Hospital in St. Johns Wood, London within 1-2 weeks. At the same time, blood samples will also be obtained for bio-markers. A report of the CTCA will then be forwarded to the consultant in-charge of the patient's care as well as to the GP.
If a narrowing of moderate degree (70%) is noted on the CT angiogram, the patient will then be brought back to the Wellington Hospital within 2 weeks for a heart perfusion scan which evaluates the relative discrepancies in flow of blood to the heart muscle and helps plan further management.
If there is significant reduction in blood flow noted in the perfusion scan,patients will be referred back to the consultants for further clinical management.
During their first visit to the Wellington Hospital for the CT scan, blood samples will be taken and stored on-site for biomarker analysis.
Patients will be followed up after 18 months from the time of recruitment into the trial,when a second CTCA, ultrasound of the arteries of the neck will be performed to assess the degree of progression of calcium and cholesterol deposits within the coronary arteries and thickness of the lining of the arteries in the neck in addition to blood sample collection for bio-markers.
Patients with significant narrowing of coronary arteries (>70%) requiring a stent to be inserted in the first scan will be excluded from follow up. Patients with normal coronary arteries on the initial scan also will be excluded from the follow-up.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, NW3 2QG
- Recruiting
- Royal Free Hospital
-
Contact:
- Shreenidhi M Venuraju, MRCP
- Phone Number: +442074835062
- Email: shreenidhimv@gmail.com
-
Principal Investigator:
- Roby Rakhit, MD FRCP
-
Sub-Investigator:
- Miranda Rosenthal, MRCP PhD
-
Sub-Investigator:
- Devaki R Nair, MSc MRCPath FRCPath
-
Sub-Investigator:
- Pierre Bouloux, MD
-
Sub-Investigator:
- Dipesh Patel, MRCP PhD
-
London, United Kingdom, EC1A 7BE
- Not yet recruiting
- Barts Health NHS Trust
-
Contact:
- Shreenidhi M Venuraju, MRCP
- Phone Number: +442074835062
- Email: shreenidhimv@gmail.com
-
Principal Investigator:
- Rajiv A Amersey, MD FRCP
-
London, United Kingdom, EN5 3DJ
- Recruiting
- Barnet Hospital
-
Contact:
- Shreenidhi M Venuraju, MRCP
- Phone Number: +442074835062
- Email: shreenidhimv@gmail.com
-
Principal Investigator:
- Mark Cohen, FRCP PhD
-
London, United Kingdom, NW1 2BU
- Not yet recruiting
- University College London Hospitals
-
Contact:
- Shreenidhi M Venuraju, MRCP
- Phone Number: +442074835062
- Email: shreenidhimv@gmail.com
-
Principal Investigator:
- Sarita Naik, DM MRCP
-
-
Middlesex
-
London, Middlesex, United Kingdom, NW10 7NS
- Recruiting
- Central Middlesex Hospital
-
Contact:
- Shreenidhi M Venuraju, MRCP
- Phone Number: +442074835062
- Email: shreenidhimv@gmail.com
-
Principal Investigator:
- Daniel Darko, MRCP
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Established T2DM with or without micro-vascular complications of diabetes (retinopathy, peripheral neuropathy and/or micro-albuminuria)
No history of coronary artery disease (CAD)
Exclusion Criteria:
- 1. Estimated GFR <45 2. Pregnant women 3. Age < 35 years 4. Atrial fibrillation 5. Known allergy to iodine contrast 6. CAC score >1000 Agatston Units
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Asymptomatic type 2 diabetes
Patients without previous history of coronary artery disease
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Greater than 20% increase in plaque volume
Time Frame: 18 months
|
Plaque volume will be measured by both manual and semi-quantitative methods
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Greater than 20% increase in coronary artery calcium score
Time Frame: 18 months
|
Coronary artery calcium scoring will be performed using a semi-quantitative method.
|
18 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between increase in plaque volume with levels of biomarkers
Time Frame: 18 months
|
Correlate plaque progression with various bio-markers
|
18 months
|
Correlation between carotid IMT measurements and coronary plaque
Time Frame: 18 months
|
Once at baseline and then during follow-up
|
18 months
|
Incidence of major adverse cardiovascular events (MACE) during the 18-month follow-up period. MACE is defined as incidence of cardiac death, non-fatal myocardial infarction, STEMI and NSTEMI, unstable angina, late revascularization and onset of angina
Time Frame: 18 months
|
Through questionnaires and medical records
|
18 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Roby Rakhit, MD FRCP, Royal Free Hospital NHS Foundation Trust
- Study Director: Avijit Lahiri, MRCP FACC, Wellington Hospital
- Principal Investigator: Daniel Darko, MRCP, Central Middlesex Hospital
- Principal Investigator: Mark Cohen, PhD FRCP, Barnet Hospital
- Principal Investigator: Rajiv A Amersey, MD FRCP, Whipps Cross Hospital
- Principal Investigator: Sarita Naik, DM MRCP, University College London Hospital
Publications and helpful links
General Publications
- Anand DV, Lim E, Lahiri A, Bax JJ. The role of non-invasive imaging in the risk stratification of asymptomatic diabetic subjects. Eur Heart J. 2006 Apr;27(8):905-12. doi: 10.1093/eurheartj/ehi441. Epub 2005 Aug 8.
- Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006 May 2;47(9):1850-7. doi: 10.1016/j.jacc.2005.12.054. Epub 2006 Apr 19.
- Anand DV, Lim E, Darko D, Bassett P, Hopkins D, Lipkin D, Corder R, Lahiri A. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol. 2007 Dec 4;50(23):2218-25. doi: 10.1016/j.jacc.2007.08.032. Epub 2007 Nov 19.
- Fredrikson GN, Anand DV, Hopkins D, Corder R, Alm R, Bengtsson E, Shah PK, Lahiri A, Nilsson J. Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia. 2009 Jul;52(7):1426-33. doi: 10.1007/s00125-009-1377-9. Epub 2009 May 12.
- Jeevarethinam A, Venuraju S, Weymouth M, Atwal S, Lahiri A. Carotid intimal thickness and plaque predict prevalence and severity of coronary atherosclerosis: a pilot study. Angiology. 2015 Jan;66(1):65-9. doi: 10.1177/0003319714522849. Epub 2014 Feb 26.
- Venuraju SM, Lahiri A, Jeevarethinam A, Cohen M, Darko D, Nair D, Rosenthal M, Rakhit RD. Duration of type 2 diabetes mellitus and systolic blood pressure as determinants of severity of coronary stenosis and adverse events in an asymptomatic diabetic population: PROCEED study. Cardiovasc Diabetol. 2019 Apr 23;18(1):51. doi: 10.1186/s12933-019-0855-8.
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BCRT/3277/PROCEED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina